E
RedHill Biopharma Ltd.
RDHL
$2.15
$0.0984.78%
E
Sell
3/14/2023Downgrade
RedHill Biopharma Ltd. (RDHL) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index.
RedHill Biopharma Ltd. (RDHL) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index.
D
Sell
2/23/2023Upgraded
RedHill Biopharma Ltd. (RDHL) was upgraded to D- from E+ on 02/23/2023.
RedHill Biopharma Ltd. (RDHL) was upgraded to D- from E+ on 02/23/2023.
E
Sell
2/8/2023Downgrade
RedHill Biopharma Ltd. (RDHL) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index and volatility index.
RedHill Biopharma Ltd. (RDHL) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index and volatility index.
D
Sell
12/7/2022Downgrade
RedHill Biopharma Ltd. (RDHL) was downgraded to D- from D on 12/7/2022 due to a significant decline in the solvency index, growth index and volatility index. Earnings per share declined from -$2.061 to -$5.593, debt to equity increased from -7.28 to -2.49, and the quick ratio declined from 0.37 to 0.26.
RedHill Biopharma Ltd. (RDHL) was downgraded to D- from D on 12/7/2022 due to a significant decline in the solvency index, growth index and volatility index. Earnings per share declined from -$2.061 to -$5.593, debt to equity increased from -7.28 to -2.49, and the quick ratio declined from 0.37 to 0.26.
D
Sell
5/16/2022Upgraded
RedHill Biopharma Ltd. (RDHL) was upgraded to D from E+ on 05/16/2022.
RedHill Biopharma Ltd. (RDHL) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
RedHill Biopharma Ltd. (RDHL) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index and volatility index.
RedHill Biopharma Ltd. (RDHL) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index and volatility index.
D
Sell
5/4/2022Upgraded
RedHill Biopharma Ltd. (RDHL) was upgraded to D from E+ on 05/04/2022.
RedHill Biopharma Ltd. (RDHL) was upgraded to D from E+ on 05/04/2022.
E
Sell
5/1/2022Downgrade
RedHill Biopharma Ltd. (RDHL) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index and volatility index.
RedHill Biopharma Ltd. (RDHL) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index and volatility index.
D
Sell
4/21/2022Upgraded
RedHill Biopharma Ltd. (RDHL) was upgraded to D from E+ on 04/21/2022.
RedHill Biopharma Ltd. (RDHL) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
RedHill Biopharma Ltd. (RDHL) was downgraded to E+ from D on 4/20/2022 due to a large decline in the solvency index, total return index and volatility index. Debt to equity increased from 7.38 to 9.6.
RedHill Biopharma Ltd. (RDHL) was downgraded to E+ from D on 4/20/2022 due to a large decline in the solvency index, total return index and volatility index. Debt to equity increased from 7.38 to 9.6.
D
Sell
11/23/2021Upgraded
RedHill Biopharma Ltd. (RDHL) was upgraded to D from D- on 11/23/2021.
RedHill Biopharma Ltd. (RDHL) was upgraded to D from D- on 11/23/2021.
D
Sell
11/8/2021Downgrade
RedHill Biopharma Ltd. (RDHL) was downgraded to D- from D on 11/8/2021 due to a decline in the volatility index and total return index.
RedHill Biopharma Ltd. (RDHL) was downgraded to D- from D on 11/8/2021 due to a decline in the volatility index and total return index.
D
Sell
9/22/2021Downgrade
RedHill Biopharma Ltd. (RDHL) was downgraded to D from D+ on 9/22/2021 due to a decline in the total return index and volatility index.
RedHill Biopharma Ltd. (RDHL) was downgraded to D from D+ on 9/22/2021 due to a decline in the total return index and volatility index.
D
Sell
9/7/2021Upgraded
RedHill Biopharma Ltd. (RDHL) was upgraded to D+ from D on 9/7/2021 due to an increase in the growth index, solvency index and volatility index. The quick ratio increased from 0.81 to 1.49, debt to equity declined from 5.99 to 1.59, and earnings per share increased from -$6.423 to -$5.322.
RedHill Biopharma Ltd. (RDHL) was upgraded to D+ from D on 9/7/2021 due to an increase in the growth index, solvency index and volatility index. The quick ratio increased from 0.81 to 1.49, debt to equity declined from 5.99 to 1.59, and earnings per share increased from -$6.423 to -$5.322.
D
Sell
4/7/2021Downgrade
RedHill Biopharma Ltd. (RDHL) was downgraded to D from D+ on 4/7/2021 due to a decline in the volatility index and total return index.
RedHill Biopharma Ltd. (RDHL) was downgraded to D from D+ on 4/7/2021 due to a decline in the volatility index and total return index.
D
Sell
3/23/2021Upgraded
RedHill Biopharma Ltd. (RDHL) was upgraded to D+ from D on 3/23/2021 due to an increase in the volatility index.
RedHill Biopharma Ltd. (RDHL) was upgraded to D+ from D on 3/23/2021 due to an increase in the volatility index.
D
Sell
3/18/2021Downgrade
RedHill Biopharma Ltd. (RDHL) was downgraded to D from D+ on 3/18/2021 due to a decline in the growth index and volatility index. EBIT declined 15.68% from -$12.5M to -$14.46M, and earnings per share declined from -$4.487 to -$4.998.
RedHill Biopharma Ltd. (RDHL) was downgraded to D from D+ on 3/18/2021 due to a decline in the growth index and volatility index. EBIT declined 15.68% from -$12.5M to -$14.46M, and earnings per share declined from -$4.487 to -$4.998.
D
Sell
8/17/2020Upgraded
RedHill Biopharma Ltd. (RDHL) was upgraded to D+ from D on 8/17/2020 due to a noticeable increase in the total return index, growth index and volatility index. Total revenue increased 1,879.07% from $1.06M to $20.9M, EBIT increased 22.84% from -$16.2M to -$12.5M, and earnings per share increased from -$4.865 to -$4.487.
RedHill Biopharma Ltd. (RDHL) was upgraded to D+ from D on 8/17/2020 due to a noticeable increase in the total return index, growth index and volatility index. Total revenue increased 1,879.07% from $1.06M to $20.9M, EBIT increased 22.84% from -$16.2M to -$12.5M, and earnings per share increased from -$4.865 to -$4.487.
D
Sell
5/1/2020Upgraded
RedHill Biopharma Ltd. (RDHL) was upgraded to D from D- on 5/1/2020 due to an increase in the valuation index.
RedHill Biopharma Ltd. (RDHL) was upgraded to D from D- on 5/1/2020 due to an increase in the valuation index.
D
Sell
2/21/2020Upgraded
RedHill Biopharma Ltd. (RDHL) was upgraded to D- from E+ on 2/21/2020 due to a large increase in the solvency index, growth index and valuation index. Operating cash flow increased 14.91% from -$10.45M to -$8.89M, and earnings per share increased from -$0.385 to -$0.347.
RedHill Biopharma Ltd. (RDHL) was upgraded to D- from E+ on 2/21/2020 due to a large increase in the solvency index, growth index and valuation index. Operating cash flow increased 14.91% from -$10.45M to -$8.89M, and earnings per share increased from -$0.385 to -$0.347.
E
Sell
11/14/2019Downgrade
RedHill Biopharma Ltd. (RDHL) was downgraded to E+ from D- on 11/14/2019 due to a major decline in the growth index, total return index and solvency index. Debt to equity increased from 0.02 to 0.03, operating cash flow declined 38.76% from -$7.53M to -$10.45M, and the quick ratio declined from 3.88 to 2.55.
RedHill Biopharma Ltd. (RDHL) was downgraded to E+ from D- on 11/14/2019 due to a major decline in the growth index, total return index and solvency index. Debt to equity increased from 0.02 to 0.03, operating cash flow declined 38.76% from -$7.53M to -$10.45M, and the quick ratio declined from 3.88 to 2.55.
D
Sell
7/1/2019Upgraded
RedHill Biopharma Ltd. (RDHL) was upgraded to D- from E+ on 7/1/2019 due to a large increase in the growth index, solvency index and total return index. Total revenue increased 27.81% from $1.36M to $1.74M, EBIT increased 8.26% from -$10.04M to -$9.21M, and operating cash flow increased 8.07% from -$8.19M to -$7.53M.
RedHill Biopharma Ltd. (RDHL) was upgraded to D- from E+ on 7/1/2019 due to a large increase in the growth index, solvency index and total return index. Total revenue increased 27.81% from $1.36M to $1.74M, EBIT increased 8.26% from -$10.04M to -$9.21M, and operating cash flow increased 8.07% from -$8.19M to -$7.53M.
E
Sell
12/19/2018Downgrade
RedHill Biopharma Ltd. (RDHL) was downgraded to E+ from D- on 12/19/2018 due to a decline in the volatility index.
RedHill Biopharma Ltd. (RDHL) was downgraded to E+ from D- on 12/19/2018 due to a decline in the volatility index.
D
Sell
7/10/2018Upgraded
RedHill Biopharma Ltd. (RDHL) was upgraded to D- from E+ on 7/10/2018 due to a major increase in the growth index and volatility index. Operating cash flow increased 32.96% from -$14.17M to -$9.5M, EBIT increased 26.08% from -$13.52M to -$10M, and total revenue increased 22.19% from $2M to $2.45M.
RedHill Biopharma Ltd. (RDHL) was upgraded to D- from E+ on 7/10/2018 due to a major increase in the growth index and volatility index. Operating cash flow increased 32.96% from -$14.17M to -$9.5M, EBIT increased 26.08% from -$13.52M to -$10M, and total revenue increased 22.19% from $2M to $2.45M.
E
Sell
11/3/2017Downgrade
RedHill Biopharma Ltd. (RDHL) was downgraded to E+ from D- on 11/3/2017 due to a decline in the volatility index and valuation index.
RedHill Biopharma Ltd. (RDHL) was downgraded to E+ from D- on 11/3/2017 due to a decline in the volatility index and valuation index.
D
Sell
9/20/2017Upgraded
RedHill Biopharma Ltd. (RDHL) was upgraded to D- from E+ on 9/20/2017 due to an increase in the volatility index and total return index.
RedHill Biopharma Ltd. (RDHL) was upgraded to D- from E+ on 9/20/2017 due to an increase in the volatility index and total return index.
E
Sell
9/5/2017Downgrade
RedHill Biopharma Ltd. (RDHL) was downgraded to E+ from D- on 9/5/2017 due to a decline in the volatility index.
RedHill Biopharma Ltd. (RDHL) was downgraded to E+ from D- on 9/5/2017 due to a decline in the volatility index.
D
Sell
8/18/2017Upgraded
RedHill Biopharma Ltd. (RDHL) was upgraded to D- from E+ on 8/18/2017 due to an increase in the volatility index and valuation index.
RedHill Biopharma Ltd. (RDHL) was upgraded to D- from E+ on 8/18/2017 due to an increase in the volatility index and valuation index.
E
Sell
7/27/2017Downgrade
RedHill Biopharma Ltd. (RDHL) was downgraded to E+ from D- on 7/27/2017 due to a large decline in the solvency index, growth index and efficiency index. The quick ratio declined from 10.47 to 4.91, EBIT declined 34.02% from -$10.1M to -$13.54M, and net income declined 28.23% from -$8.6M to -$11.02M.
RedHill Biopharma Ltd. (RDHL) was downgraded to E+ from D- on 7/27/2017 due to a large decline in the solvency index, growth index and efficiency index. The quick ratio declined from 10.47 to 4.91, EBIT declined 34.02% from -$10.1M to -$13.54M, and net income declined 28.23% from -$8.6M to -$11.02M.
D
Sell
2/27/2017Upgraded
RedHill Biopharma Ltd. (RDHL) was upgraded to D- from E+ on 2/27/2017 due to an increase in the growth index, solvency index and efficiency index. The quick ratio increased from 5.56 to 12.44, total capital increased 54.87% from $40.49M to $62.7M, and net income increased 6.64% from -$8.94M to -$8.35M.
RedHill Biopharma Ltd. (RDHL) was upgraded to D- from E+ on 2/27/2017 due to an increase in the growth index, solvency index and efficiency index. The quick ratio increased from 5.56 to 12.44, total capital increased 54.87% from $40.49M to $62.7M, and net income increased 6.64% from -$8.94M to -$8.35M.
E
Sell
2/1/2017Downgrade
RedHill Biopharma Ltd. (RDHL) was downgraded to E+ from D- on 2/1/2017 due to a major decline in the total return index, valuation index and volatility index.
RedHill Biopharma Ltd. (RDHL) was downgraded to E+ from D- on 2/1/2017 due to a major decline in the total return index, valuation index and volatility index.
D
Sell
12/14/2016Downgrade
RedHill Biopharma Ltd. (RDHL) was downgraded to D- from D on 12/14/2016 due to a decline in the solvency index, volatility index and valuation index. The quick ratio declined from 7.07 to 5.56.
RedHill Biopharma Ltd. (RDHL) was downgraded to D- from D on 12/14/2016 due to a decline in the solvency index, volatility index and valuation index. The quick ratio declined from 7.07 to 5.56.
D
Sell
4/18/2016Upgraded
RedHill Biopharma Ltd. (RDHL) was upgraded to D from D- on 4/18/2016 due to an increase in the volatility index and total return index.
RedHill Biopharma Ltd. (RDHL) was upgraded to D from D- on 4/18/2016 due to an increase in the volatility index and total return index.
D
Sell
3/11/2016Downgrade
RedHill Biopharma Ltd. (RDHL) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, growth index and total return index. Total revenue declined 100% from $1 to $0, operating cash flow declined 60.92% from -$3.75M to -$6.03M, and EBIT declined 45.14% from -$4.59M to -$6.67M.
RedHill Biopharma Ltd. (RDHL) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, growth index and total return index. Total revenue declined 100% from $1 to $0, operating cash flow declined 60.92% from -$3.75M to -$6.03M, and EBIT declined 45.14% from -$4.59M to -$6.67M.
D
Sell
3/6/2015None
RedHill Biopharma Ltd. (RDHL) was downgraded to D from U on 03/06/2015.
RedHill Biopharma Ltd. (RDHL) was downgraded to D from U on 03/06/2015.
NASDAQ
04/08/2025 9:47AM Eastern
Quotes delayed
